Clovis Oncology Inc. (NASDAQ:CLVS) has announced that Rubraca (rucaparib) tablets have been approved for the treatment of BRCA-mutant mCRPC in a second-line setting as well as subsequent therapy.
NCCN updates clinical guidelines to include rubraca in mCRPC
The company indicated that the National Comprehensive Cancer Network updated the Clinical Practice Guidelines in Oncology for Prostate Cancer, including Rubraca. Besides the recommendation to treat ovarian cancer, Rubraca will now be used as a Category 21 recommendation for treating mCRPC in BRCA-mutant patients.
The recommendation also includes the use of the drug as an option in treating mCRPC and BRCA2 mutation or pathogenic BRCA1 patients that have been under taxane-based chemo or androgen receptor directed treatment. As a result, if chemotherapy doesn’t fit a patient, they can consider rucapari even if they have not received taxane-based therapy.
Patrick Mahaffy, the CEO and President of Clovis Oncology stated that they were delighted to get acknowledgment from NCCN regarding the significance of novel targeted therapies aimed at treating prostate cancer and the need for treatment alternatives for BRCA mutations patients. Rubraca is the first approved PARP inhibitor for such patients.
Approval of Rubraca in treatment mCRPC patients huge milestone amid COVID-19
The CEO said that this a huge step considering during this COVID-19 period, most patients will not prefer chemotherapy that needs regular clinical visits. They will instead go for an oral agent that they can take at home, which is directly delivered.
Normally the NCCN Guidelines are acknowledged as the standard for clinical policy and direction in cancer care. They are the most frequent and thoroughly updated practice guidelines that are available in most areas of medicine. The decision of NCCN to include Rubraca for prostate cancer as a Category 2A treatment alternative for MRCA mutation patients was based in the second Phase TRITON2 study. Rubraca has been indicated for the treatment of deleterious BRCA mutation related to mCRPC adult patients who have received treatment through taxane-based chemotherapy or androgen receptor aided therapy.